Abstract:Bladder cancer ranks as the second most prevalent urology malignancy globally. Invasive metastasis is a significant contributor to mortality among patients with bladder cancer, yet the underlying mechanisms remain elusive. Deubiquitinases are pivotal in carcinogenesis, with USP5 implicated in the malignant progression of hepatocellular carcinoma, colorectal cancer and non‐small cell lung cancer. The present study assessed the role and mechanism of ubiquitin‐specific proteinase 5 (USP5) in the malignant progression of bladder cancer. The association between USP5 expression and bladder cancer prognosis and stage was analyzed using The Cancer Genome Atlas database. Moreover, to elucidate the role of USP5 in bladder cancer, USP5 overexpression and knockdown cell lines were established using T24 cells. Cell viability, proliferation and migration were assessed using Cell Counting Kit‐8, Transwell and scratch assays, respectively. Cyclohexanamide was used to evaluate the effect of USP5 expression on Snail family zinc finger 2 (SLUG) stability. Immunoprecipitation and immunofluorescence co‐localization were utilized to probe the interaction between USP5 and SLUG. Changes in mRNA and protein levels were assessed using reverse transcription‐quantitative PCR and western blotting, respectively. The results revealed that patients with bladder cancer with high USP5 expression had significantly shorter survival (P<0.05) and a higher clinicopathologic stage (P<0.05) than those with low USP5 expression. T24 cells overexpressing USP5 demonstrated significantly increased proliferation (P<0.05), invasion (P<0.05) and expression of epithelial‐mesenchymal transition markers (P<0.05); whereas T24 cells with knocked‐down USP5 expression revealed significantly reduced proliferation (P<0.05), invasion (P<0.05) and epithelial‐mesenchymal transition markers (P<0.05). Immunoprecipitation experiments demonstrated the binding of USP5 to SLUG in bladder cancer cells, with further analysis revealing that USP5 upregulated protein levels of SLUG by inhibiting its ubiquitination. Furthermore, the treatment of bladder cancer cells with Degrasyn, a USP5 inhibitor, was associated with a significant inhibition of the proliferation (P<0.05) and invasion (P<0.05) of T24 cells. In conclusion, the findings of the present study underscore the role of USP5 in promoting the malignant progression of bladder cancer through the stabilization of SLUG. Targeting USP5 holds promise as a strategy for inhibiting bladder cancer progression.

The deubiquitinase USP5 promotes cholangiocarcinoma progression by stabilizing YBX1

USP54 is a potential therapeutic target in castration-resistant prostate cancer

Deubiquitinase USP5 promotes non-small cell lung cancer cell proliferation by stabilizing cyclin D1

The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization.

USP1 promotes cholangiocarcinoma progression by deubiquitinating PARP1 to prevent its proteasomal degradation

Ubiquitin specific peptidase 5 regulates colorectal cancer cell growth by stabilizing Tu translation elongation factor.

Correction to: USP20 positively regulates tumorigenesis and chemoresistance through β-catenin stabilization

USP21 deubiquitinates and stabilizes HSP90 and ENO1 to promote aerobic glycolysis and proliferation in cholangiocarcinoma

Operative ubiquitin-specific protease 22 deubiquitination confers a more invasive phenotype to cholangiocarcinoma

USP5 facilitates bladder cancer progression by stabilizing the c-Jun protein

Deubiquitinase USP18 Promotes the Progression of Pancreatic Cancer Via Enhancing the Notch1-c-Myc Axis.

USP5 promotes tumor progression by stabilizing SLUG in bladder cancer

Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression by Stabilizing c-MYC

Ubiquitin-specific Protease 15 Contributes to Gastric Cancer Progression by Regulating the Wnt/β-catenin Signaling Pathway.

USP5 Promotes Tumorigenesis and Progression of Pancreatic Cancer by Stabilizing FoxM1 Protein.

Usp5 Functions As An Oncogene For Stimulating Tumorigenesis In Hepatocellular Carcinoma

USP5 Promotes Epithelial-Mesenchymal Transition by Stabilizing SLUG in Hepatocellular Carcinoma.

The deubiquitinating enzyme USP19 facilitates hepatocellular carcinoma progression through stabilizing YAP

USP5 facilitates non-small cell lung cancer progression through stabilization of PD-L1

The ubiquitin‐specific protease 5 mediated deubiquitination of LSH links metabolic regulation of ferroptosis to hepatocellular carcinoma progression

Deubiquitinating enzyme USP46 suppresses the progression of hepatocellular carcinoma by stabilizing MST1